The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?

Mature overall survival (OS) data are often unavailable at the time of regulatory and reimbursement decisions for a new cancer treatment. For patients with early-stage cancers treated with potentially curative treatments, demonstrating an OS benefit may take years and may be confounded by subsequent...

Descripción completa

Detalles Bibliográficos
Autores principales: Lux, Michael Patrick, Ciani, Oriana, Dunlop, William C N, Ferris, Andrea, Friedlander, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592394/
https://www.ncbi.nlm.nih.gov/pubmed/34795526
http://dx.doi.org/10.2147/CMAR.S328058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592394/
https://www.ncbi.nlm.nih.gov/pubmed/34795526
http://dx.doi.org/10.2147/CMAR.S328058

Ejemplares similares